Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A. Philip, Pascal Hammel, Roberto Pazo-Cid et al.|The Lancet. Gastroenterology & hepatology|2020Cited by 249
LAPACT: An open-label, multicenter phase II trial of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).Philip Agop Philip, Pascal Hammel, Jill Lacy et al.|Journal of Clinical Oncology|2016Cited by 3